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metastatic colorectal adenocarcinoma:
a persisting diagnostic challenge
Somak Roy1, Matthew A Smith1, Kathy M Cieply1,2, Marie B Acquafondata1 and Anil V Parwani1,3*Abstract
Aim: This study attempted to distinguish primary bladder adenocarcinoma (PBA) from metastatic colonic
adenocarcinomas (MCA), which is a difficult diagnostic and clinical problem.
Methods: Twenty-four cases of bladder adenocarcinomas (12 primary & 12 metastatic colorectal) were included in
the study with urothelial carcinoma (UC) and colonic adenocarcinoma (CA) as controls. A panel of
immunohistochemical (IHC) stains along with fluorescence in-situ hybridization (FISH), using the UroVysion probe
set, was performed.
Results: The majority of the PBAs presented with advanced disease. Enteric histologic subtype was the most
common morphological variant. Strong nuclear with cytoplasmic-membranous staining of β-catenin was seen in
75% of MCA and only 16.7% PBA (<10% staining cells). Although abnormal nuclear staining with E-cadherin was
seen in both PBA and MCA, it was more frequent in former. CK-7, CK-20, villin and CDX-2 stains were not helpful in
distinguishing the two entities. FISH did not reveal any unique differences in chromosomal abnormality between
the two groups.
Conclusion: Although there was a statistically significant difference in β-catenin and E-cadherin staining between
two groups, we did not find any IHC or FISH marker that was specific for PBA. Distinction between PBA and MCA
remains a diagnostic problem and clinical correlation is vital before rendering a diagnosis.
Virtual slides: The virtual slides for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1393156268152357
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Primary bladder adenocarcinoma (PBA), histologically
comprised entirely or almost entirely of malignant glan-
dular elements, is a rare tumor accounting for 0.5-2% of
all malignant vesical tumors [1-3]. This glandular tumor,
like other variants, arises through a process of divergent
differentiation in urothelial carcinoma, which is extensive
enough to predominate as the only histological compo-
nent [1,4-6]. It is more frequent in males in their sixth
decade of life, presenting with hematuria and symptoms* Correspondence: parwaniav@upmc.edu
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reproduction in any medium, provided the orattributable to bladder irritation [1,7]. Two-thirds of PBA
arise in the bladder cavity, especially in the posterior
wall and trigone, and Approximately one-third originate
from urachal remnants near the dome and anterior wall
of the bladder [7,8]. Based on this, it is broadly classified
as non-urachal and urachal adenocarcinoma, respect-
ively. Although both subtypes of PBA have remarkably
similar histological and immunohistochemical features,
urachal subtype requires specific diagnostic criteria, put
forth by Sheldon et al. [9] and Mostofi et al [10]. PBAs
usually have associated surface glandular metaplasia or
cystitis glandularis in the surrounding urothelial lining;
however this is often difficult to document on small blad-
der biopsies and trans-urethral resection specimens due
to ulcerated and cauterized epithelium. Approximately. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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are adenocarcinomas [7]. Additional risk factors include
Schistsoma infection, villous adenoma and cystocele.
[2,11-13] PBA is an aggressive malignancy with a ten-
dency to present at a higher stage and is associated with
a worse overall survival [1,2,13].
The more common secondary bladder adenocarcinomas
include hematogenous, lymphatic or direct spread of
adenocarcinoma from surrounding organs, especially
colo-rectum, female genital tract, prostate, and urothelial
carcinoma with focal glandular differentiation. Metastatic
colonic adenocarcinoma (MCA) accounts for approxi-
mately one third of secondary bladder tumors and is
virtually indistinguishable from PBA based on histomor-
phology and ultrastructural features. Evidence of cystitis
glandularis or intestinal metaplasia can be a helpful clue in
establishing the diagnosis of primary bladder adenocarcin-
oma; however, MCAs have been reported to colonize the
surface urothelium and mimic in-situ glandular lesions
[3,7,14,15].
There are relatively limited numbers of studies that
have looked into the role of immunohistochemistry in
differentiating PBA from secondary bladder carcinoma,
specifically MCA [2,3,14-17]. The role of β-catenin in
differentiating PBA from MCA was first reported by
Wang et al. [3] in 2001. They attempted to analyze ab-
normal nuclear localization of β-catenin in colonic
adenocarcinomas (CA) due to dysregulation of the wnt
pathway, in the setting of PBA. Currently, there is lim-
ited published data on the use of β-catenin in differenti-
ating PBA from MCA [2,3,14,18]. In this study, we
analyzed the role of a panel of six IHC stains in differen-
tiating PBA from MCA. We also attempted to detect
any difference in underlying chromosomal abnormality
by FISH using UroVysion probe set.
Materials and methods
The Institutional Review Board of University of
Pittsburgh approved this study.Twenty-four cases of
bladder adenocarcinomas diagnosed and treated at Uni-
versity of Pittsburgh Medical Center between 1999 and
2010 were identified which included 12 cases each of
PBA and MCA. We also included 5 cases each of
urothelial carcinoma (UC) and colonic adenocarcinomaTable 1 Details of immunohistochemical panel
Antibody Type
Cytokeratin 7 Rabbit-Monoclonal




E-cadherin Mouse Monoclonal(CA) as controls in this study. Formalin-fixed, paraffin
embedded tissue blocks along with hematoxylin and
eosin (H&E) stained slides were retrieved from the
archives. The pathologists, in order to confirm the diag-
nosis and exclude urothelial carcinoma with focal glan-
dular differentiation, reviewed the slides independently.
Cystoscopic, colonoscopic and radiological findings were
reviewed to confirm the origin, location and stage of the
tumor.
A panel of immunohistochemical stains was performed
on formalin-fixed, paraffin embedded, unstained sections
from each case (Table 1). Briefly, sections were cut at
5μ and mounted on Superfrost Plus slides and dried.
Sections were deparaffinized and hydrated to deionized
water. Heat induced epitope retrieval using Citrate buffer
(pH 6, DAKO, Carpinteria, CA) was performed followed
by endogenous Peroxidase quenching using 3% Hydrogen
peroxide (Fisher Scientific, Houston, TX) and blocking
(CAS, Invitrogen, Carlsbad, CA) for 10 minutes. Slides
were incubated with primary antibody for 30–45 minutes,
secondary antibody (Mach 2 Mouse HRP, Biocare,
Concord, CA) for 30 minutes and substrate chromogen
(DAKO, Carpinteria, CA) for 5 minutes. Slides were
washed with TBS buffer between the incubations and
finally counterstained with Harris hematoxylin, dehy-
drated, cleared and cover slipped.
Cytoplasmic staining with membrane accentuation
(CM) was considered the normal pattern of staining with
β-catenin. Nuclear (N) staining was considered abnormal.
CM staining was the expected pattern for E-cadherin
whereas nuclear (N) staining was abnormal. Apical brush
border staining pattern was considered positive for villin.
Nuclear immunoexpression was the expected pattern
with CDX2 antibody and cytoplasmic staining was con-
sidered positive for CK7 and CK20 (Table 1).
A total of nine cases (5 PBA & 4 MCA) were available
for Fluorescence in-situ hybridization (FISH), which was
performed using the UroVysion probe set (Abbott
Molecular, Inc., Des Plaines, IL). Five cases each of UC
and MCA were used as controls. Briefly, formalin-fixed
paraffin-embedded sections, were mounted, and serially
sectioned at 5μ intervals. The area of interest was demar-
cated using an H&E stained slide. FISH slides were
deparaffinized in xylene, dehydrated with 100% ethanolDilution Source
1:100 Biocare Medical, Concord, CA
1:200 Biocare Medical, Concord, CA
1:100 Biocare Medical, Concord, CA
1:100 Biocare Medical, Concord, CA
1:200 DAKO, Carpinteria, CA
1:2000 BD Transduction Labs, San Jose, CA
Table 2 Clinical features of primary bladder adenocarcinoma





1 63 F Posterior 3.6 Cystourethrectomy T4aN2M0 33 AWD£ Lymph node
metastasis
2 54 F Posterior &
Lateral
4 Radical cystectomy T4bN2M0 16 NED∂
3 87 M Posterior 6 Partial cystectomy T1N0M0 13 NED
4 53 M Anterior 3.6 Partial cystectomy T3N0M0 4 NED
5 70 M Posterior 6.8 TURBT‡ T4N0M0 2 DOD€
6 62 M Posterior 3.5 TURBT‡ T2bN0M1 18 AWD Lung and pleural
metastasis
7 59 M Anterior 2.9 Partial cystectomy T3aN0M0 132 NED
8 59 M Anterior 2.9 Partial cystectomy T3aN0M0 128 NED
9 62 M Anterior 4 Radical cystectomy T4N0M0 36 AWD Lung and pleural
metastasis
10 80 M Posterior &
Anterior
8 Radical cystectomy T3aN1M0 2 AWD Multiple bony
metastasis
11 56 M Posterior 5 Radical cystoprostatectomy T3aN2M0 4 NED
12 70 M Multifocal† 0.3-0.7 Radical cystoprostatectomy T2aN0M0 2 NED
† − Tumor located predominantly in posterior wall with other tumor nodules in anterior and lateral walls. ‡ − TURBT – Transurethral resection of bladder tumor.
∂ - NED – No evidence of disease. € - DOD – Died of disease. £ - AWD – Alive with disease. ¥ -Pathologic stage.
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then digested in protease solution at 37°C. The target
slide and probe were co-denatured at 90 C for 12 min-
utes and incubated overnight at 37°C in a humidified
chamber. Post-hybridization washes were performed
using 2XSSC/0.3% Igepal at 72°C for 2 minutes. Slides
were air-dried in the dark and counterstained with DAPI I
(Abbott Molecular, Des Plaines, IL). Analysis was per-
formed using an Applied Imaging Workstation equipped
with Chroma Technology filters containing band excitors
for SpectrumOrange, FITC, DAPI. Only individual and
well-delineated cells were scored. Overlapping cells were
excluded from the analysis. Approximately 60 cells wereTable 3 Pathologic features of primary bladder adenocarcino
Case No Histological diagnosis M
1 MD AdenoCa (enteric)
2 PD AdenoCa (enteric)
3 MD AdenoCa (enteric)
4 MD to PD AdenoCa (enteric)
5 MD AdenoCa (enteric)
6 PD AdenoCa (SRC)
7 MD AdenoCa (enteric & mucinous)
8 MD AdenoCa (enteric & mucinous)
9 MD AdenoCa (enteric)
10 PD AdenoCa (mucinous and SRC)
11 Mucinous AdenoCa (enteric)
12 MD AdenoCa (enteric)
MD Moderately differentiated, PD Poorly differentiated, AdenoCa Adenocarcinoma,
Villous adenoma.analyzed in the targeted region. Statistical analysis was
performed using SPSS v19.0 (IBM, Armonk, NY).Results
Clinicopathologic features of primary bladder
adenocarcinoma
The clinicopathologic characteristics of 12 cases of PBA
are summarized in Tables 2 and 3. The age at presentation
ranged from 53–87 years (mean age 64.6 years) with a
male predominance [4,18]. The cases did not demonstrate
any associated predisposing conditions (Schistosomiasis,
cystocele, bladder exstrophy). The majority of the casesma
ucin SRC CC/CG Villous
+ - + -
- + + +
+ - + +
+ + - -
- - - -
+ + + +
+ - + -
+ - + -
- - + -
+ + - -
+ + + -
- - + -
SRC Signet ring cell carcinoma, CC Cystitis cystica, CG Cystitis glandularis, Villous
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(≥ pT3). Four of 12 (33.3%) PBA cases had node positive
disease and one patient (8.3%) presented with lung
metastasis (Table 2).
Follow-up data was available on all the patients
(2 months to 11 years), which is summarized in
Table 2. Seven patients (58.3%) were alive with no evi-
dence of disease and four patients (33.3%) were alive
with evidence of disease in the form of distant metastasis
(metastasis to lung and bone). Of the patients with pro-
gressive disease, case numbers 1, 9 and 10 developed
metastatic disease at 33, 36 and 2 months from the time
of diagnosis, respectively (Table 2).
Ten of the 12 (83.3%) cases of PBA were of the enteric
type with varying degrees of differentiation (Figure 1a).
Approximately two-third of the PBA cases originated in
the posterior wall of the bladder and 1/3rd were seen toFigure 1 a: Primary bladder adenocarcinoma, enteric type. Moderately
Elongated, enlarged and hyperchromatic nuclei with prominent stratificatio
bladder adenocarcinoma, mucinous type. Scattered small groups of tumor
abundant mucinous material (Hematoxylin & eosin, x200). c: Primary bladde
sheets of signet ring cells infiltrating the bladder wall (Hematoxylin & eosin
underlying invasive primary bladder adenocarcinoma (Hematoxylin & eosin
a focus of invasive primary bladder adenocarcinoma (not seen in this imag
Moderately differentiated, infiltrating malignant glands with morphological
(Hematoxylin & eosin, x100).arise from the anterior wall. The average tumor size was
4.3 cm. In case number 12, there were multiple tumor
nodules (0.3–0.7 cm) and although the tumor nodules
were predominantly in the posterior wall, additional
nodules were present in the anterior and lateral bladder
walls (multifocal). Histological variations included the
presence of mucin (8/12, 66.7%, Figure 1b) and signet
ring cells (5/12, 41.7%, Figure 1c). Cystitis cystica and
cystitis glandularis were seen in 9/12 (75%, Figure 1d, 1e)
and villous adenoma was seen in 3/12 (25%) cases. All
MCA cases were metastatic from the colon and rectum
(Figure 1f ) (Table 3).
Immunohistochemical findings
The results of immunohistochemical staining for the
PBA cases are summarized in Tables 4 and 5. All PBA
cases demonstrated CM staining with β-catenin staindifferentiated malignant glands are seen with dirty luminal necrosis.
n line the malignant glands. (Hematoxylin & eosin, x100). b: Primary
cells with intracytoplasmic mucin are seen in a background of
r adenocarcinoma, signet ring cell type: Tumor comprised of diffuse
, x200). d: Cystitis cystica involving the surface urothelium with
, x100). e: Extensive cystitis glandularis, intestinal type seen adjacent to
e) (Hematoxylin & eosin, x40). f: Metastatic colorectal adenocarcinoma.
features similar to primary bladder adenocarcinoma see in a
Table 4 Results of β-catenin and E-cadherin
immunostaining of primary bladder adenocarcinoma,
metastatic and primary colorectal adenocarcinoma and
urothelial carcinoma
PBA MCA CA UC
Beta-Catenin CM+N 2 (16.7%)* 9 (75%) 5 (100%) 0
CM only 10 (83.3%) 3 (25%) 0 5 (100%)
Total 12 12 5 5
E-cadherin CM+N 7 (58.3%) 3 (25%) 0 0
CM only 5 (41.7%) 9 (75%) 5 (100%) 5 (100%)
Total 12 12 5 5
*-Nuclear staining seen in <10% cells.
CA Colorectal adenocarcinoma, CM cytoplasmic staining with membranous
accentuation, MCA metastatic colorectal adenocarcinoma, N nuclear, UC
urothelial carcinoma.
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nuclear staining in addition (<5% cells). Nine of 12 (75%)
MCAs demonstrated strong nuclear and CM staining
(Figure 2b) and remaining (25%) did not demonstrate
nuclear staining. The control cases of CA showed strong
and diffuse nuclear as well as CM expression of β-catenin
in 4/5 (80%) cases and focal (20% cells) nuclear staining in
one case. Nuclear staining was not seen in UCs (Table 4).
CM and nuclear staining with E-cadherin was restricted
to PBA (7/12, 58.3%) and MCA (3/12, 25%) only
(Figure 2c, 2d). The difference in abnormal nuclear ex-
pression of e-cadherin between PBA and MCA was not
statistically significant (Fisher’s Exact test, p=0.214). How-
ever, when PBA was compared to MCA and CA com-
bined, the difference was statistically significant (Fisher’s
Exact test, p=0.046). (Table 5) Apical brush border
staining with villin was seen in all cases of PBA and
11/12 (91.7%) cases of MCA (Figure 3a). CDX-2 expres-
sion was documented in 10/12 (83.3%) of PBA and all
cases of MCA (Figure 3b). Four (33.3%) cases of PBA
and 1 (8.3%) case of MCA demonstrated strong CK7
expression (Figure 3c). CK20 expression was seen in all
cases of PBA and MCA (Figure 3d) (Table 5).Table 5 Results of Cytokeratin 7 & 20, villin and CDX-2
immunostaining of primary bladder adenocarcinoma,
metastatic and primary colorectal adenocarcinoma and
urothelial carcinoma
PBA MCA CA UC
Cytokeratin 7 4 (33.3%) 1 (8.3%) 0 5 (100%)
Cytokeratin 20 12 (100%) 12 (100%) 5 (100%) 2 (40%)
Villin 12 (100%) 11 (91.7%) 5 (100%) 0
CDX-2 10 (83.3%) 12 (100%) 5 (100%) 0
CA Colorectal adenocarcinoma, CM cytoplasmic staining with membranous
accentuation, MCA metastatic colorectal adenocarcinoma, UC urothelial
carcinoma.Fluorescence in-situ hybridization results
The most frequent chromosomal abnormalities detected
by UroVysion FISH in PBAs were 9p21 homozygous
loss (HL) (6/9, 67%) (Figure 4) followed by Polysomy
(PL) pattern (3/9, 33%) (Figure 5). HL, PL and single
chromosome gain of chromosome 3 (SG) were seen
in 3/5 (60%), 1/5 (20%), and 1/5 (20%) of PBA cases,
respectively. Secondary adenocarcinoma showed HL
(3/4, 75%), PL (2/4, 50%) and SG (chromosome 7) (1/4,
25%), respectively (Table 6).Discussion
Primary bladder adenocarcinoma is a rare tumor com-
prising no more than 2% of all primary vesical malig-
nancies [1-3]. in our series, the male to female ratio
was 5:1 with mean age of 64.6 years. Eight of 12 cases
(66.7%) originated from the posterior wall. Four tumors
were seen in the anterior wall near the dome. However,
they did not meet the other required criteria to be classi-
fied as urachal type adenocarcinoma. These findings were
in accordance to published literature [2,3,7,8].
The average size of tumor documented in our study
was 4.25 cm (range 0.7-6.8 cm). Histologically, PBA is
usually well to moderately differentiated and most fre-
quently are of the enteric type, comprised of glandular
structures lined by cuboidal to columnar cells with
basally located vesicular nuclei and prominent nucleoli.
The cytoplasm is usually apical with or without mucin
vacuoles, the former representing goblet cells found in
benign and malignant colonic glands. Mitoses and dirty
necrosis are frequently seen [1,3,4,7]. Varying degree of
extracellular mucin may be seen with these tumors. The
mucinous variant is comprised of abundant extracellular
pools of mucin with floating tumor cells. Additionally,
some of the tumors may also harbor signet ring cells
with intracellular mucin, the latter often referred to as
the signet ring cell variant of PBA [2,18].
In the current study, there was a predominance of
moderately differentiated PBA (75%), all of which were
of the enteric type. Extracellular mucin and signet ring
cells were seen in 66.7% and 41.7% cases, respectively.
Case #6 had predominance of signet ring cells (>75%)
and was classified as signet ring cell adenocarcinoma.
Cystitis cystica/glandularis was documented in three-
quarters of the cases and a villous adenoma like lesion
was seen in 25% cases. Other variants, such as hepatoid
and clear cell types, were not included in this study.
Secondary bladder adenocarcinoma, which is more fre-
quent than PBA, is represented by either direct extension
of tumor from surrounding organs like the rectum, colon
and female genital tract or lymphatic and hematogenous
spread of tumor. MCA is by far the most frequent type in
SBA. It is important to distinguish PBA from MCA for
Figure 2 a: Primary bladder adenocarcinoma. Strong cytoplasmic membranous staining with β-catenin (DAB chromogen, x100). b: Metastatic
colorectal adenocarcinoma. Strong nuclear staining in addition to cytoplasmic staining with β-catenin (DAB chromogen, x100). c: Primary bladder
adenocarcinoma. Strong nuclear staining with e-cadherin in addition to weaker cytoplasmic staining pattern. This pattern was more frequent in
this group of tumor in contrast to metastatic colorectal adenocarcinoma (DAB chromogen x200). d: Metastatic colorectal adenocarcinoma.
Prominent cytoplasmic membranous staining with e-cadherin. Note the absence of nuclear staining (DAB chromogen, x200).
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ment [2,3,16].
Abnormal localization of β-catenin has been well
documented in colonic adenocarcinomas with mutationFigure 3 a: Primary bladder adenocarcinoma demonstrating apical br
seen in metastatic colorectal adenocarcinoma. (DAB chromogen, x100). b:
staining with CDX-2. Metastatic colorectal adenocarcinoma demonstrated s
adenocarcinoma shows strong cytoplasmic staining with CK7. Overall, it wa
more frequently in primary than metastatic adenocarcinomas. (DAB chrom
cytoplasmic positivity for CK20. This was also seen in majority of metastaticin APC tumor suppressor gene [19]. The wild-type
APC functions to degrade free cytoplasmic β-catenin,
an important molecule in cadherin mediated cell-to-cell
adhesion system. In patients with mutated or absentush border staining with villin. Very similar staining pattern was also
Primary bladder adenocarcinoma demonstrating strong diffuse nuclear
ame staining pattern. (DAB chromogen, x100). c: Primary bladder
s infrequently seen in glandular bladder tumors, however slightly
ogen, x100). d: Primary bladder adenocarcinoma shows diffuse strong
colorectal adenocarcinoma. (DAB chromogen, x100).
Table 6 Results of FISH using UroVysion probe set
Case # FISH scores
SG PL HL
PBA
Case 1 0 0 4%
Case 2 0 0 12%
Case 3 8% (Ch 3) 0 4%
Case 4 0 8% 0
Case 5 0 0 0
MCA
Case 1 0 84% 4%
Case 2 0 52% 4%
Case 3 0 0 8%
Case 4 4% (Ch 7) 0 0
SG Single chromosome gain; PL Polysomy; HL Homozygous loss 9p21
PBA Primary bladder adenocarcinoma; MCA Metastatic colonic
adenocarcinoma Ch Chromosome; FISH fluorescence in-situ hybridization.
Figure 4 Primary bladder adenocarcinoma. FISH using UroVysion
probe set demonstrates complete loss of yellow signal in some cells
(homozygous loss 9p21) and single chromosome 3 gain in fewer
cells (>2 red signals) (Red – CEP3, Green – CEP7, Aqua – CEP17 and
Yellow – LSI 9p21, x600).
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and acts as a transactivating factor for the transcrip-
tional factor Tcf-4 to regulate the expression of a num-
ber of downstream target genes that are believed play a
role in oncogenesis [20]. Wang et al. first exploited this
finding in the setting of PBA and observed absence of
nuclear staining in all PBA and nuclear staining in 81%
MCA. This was reported to be a helpful distinction
between the two entities [3]. Subsequently, few other
studies reported the utility of β-catenin staining inFigure 5 Primary bladder adenocarcinoma. FISH using UroVysion
probe set demonstrates a polysomy pattern with more than 2 red,
green and aqua signals. (Red – CEP3, Green – CEP7, Aqua – CEP17
and Yellow – LSI 9p21, x600).settings of signet ring cell adenocarcinomas of bladder
and urachal adenocarcinomas [2,14,18]. In our study,
nuclear staining was predominantly seen in MCA and
CA unlike PBA. In two cases of PBA nuclear staining
was seen in less than 5% of the tumor cells. These find-
ings are similar to the previously reported study by
Gopalan et al. [14] who reported focal nuclear staining
(15% cells) in 1 of 24 cases of urachal adenocarcinomas.
However, the nuclear staining was seen in the clear cell
urothelial component of the tumor rather than the
adenocarcinoma component itself. Overall the differ-
ence in β-catenin staining pattern between PBA and
MCA was statistically significant (χ2 test, p=0.001).
The e-cadherin molecule forms an important compo-
nent of the cell-cell adhesion complex in association
with other proteins including catenin molecules (α-, β-,
and γ) and p120 [21]. Loss of membranous localization
of e-cadherin has been associated with invasion, metasta-
sis and aggressive behavior in many human malignancies
[21,22]. Loss of membranous staining with abnormal
nuclear localization has been reported in pituitary, pan-
creatic, esophageal and urothelial tumors [21-24]. The
mechanism of this abnormal localization is still unclear.
Loss of membranous e-cadherin expression in urothelial
carcinoma has been correlated with aggressive disease,
increased risk of nodal metastasis and death [22]. Tho-
mas et al. reported loss of membranous e-cadherin ex-
pression in approximately one-third of foci of PBA
demonstrating signet-ring cell morphology in compari-
son to colonic type PBA; however, they did not encoun-
ter abnormal nuclear localization of e-cadherin [2].
In the current study, none of the CA or UC con-
trols demonstrated nuclear staining pattern. E-cadherin
molecule is comprised of 3 domains – extracellular,
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mercially available antibody clones, 36/E clone is directed
against the cytoplasmic portion of e-cadherin. Our
results of e-cadherin are based on use of this clone.
(Table 1) The same clone was also used by the prior
studies, which reported aberrant nuclear localization of
e-cadherin [21-24].
CDX-2 is a mammalian homeobox gene, encoding a
nuclear transcription factor, which is implicated as a
tumor suppressor [16]. Nuclear staining is seen in nor-
mal colonic epithelial cells and colonic adenocarcinoma
has been reported [3,25]. CDX-2 expression was seen in
83.3% cases of PBA, all cases of MCA and CA which is
in accordance with the prior studies [3,14-16,25]. Inter-
estingly, Suh et al. [16] also reported absence of CDX-2
expression in half of the cases of PBA. Two cases
(16.7%) of PBA in our series were negative for CDX-2.
Villin is a 93-kilodalton actin-binding protein involved
in the maintenance of brush border apparatus. Its ex-
pression can be seen in gastrointestinal tract and renal
epithelial cells as well as in adenocarcinomas of gastro-
intestinal tract, pancreas, endometrium and ovary [16].
A limited number of studies have analyzed the role of
villin in distinguishing PBA from SBA which reported
overlapping staining between PBA and MCA [16-18].
We too did not find any difference in staining pattern
between the two tumor groups.
The CK7 and CK20 staining profile has been used pre-
viously in distinguishing tumors from different sites.
Gastrointestinal tumors, including colonic and rectal
adenocarcinomas, tend to be CK20+ and CK7-. For
urothelial neoplasms, the staining profile is the exact
opposite. This difference was studied previously in PBA,
but with limited success. Many PBA have been reported
to show a CK20+ and CK7- profile, similar to colonic
adenocarcinomas [3,15,17]. CK7 immunoexpression was
seen in all cases of urothelial carcinoma and one third of
PBAs. In contrast, only one (8.33%) case of SBA was
positive for CK7 and all CAs were negative. CK20 immu-
nostaining was seen in all PBAs, SBAs and colonic
adenocarcinoma. Based on these findings, CK7 appeared
to be of limited utility in distinguishing PBAs from sec-
ondary bladder adenocarcinomas and CK20 was not able
to distinguish between the two tumor groups.
We also attempted to study the molecular aspect of
PBA and MCA with a limited number of available cases
(5 PBA and 4 MCA). FISH analysis using UroVysion
probe sets were performed. To the best of our know-
ledge, our study is the first one that utilized molecular
methods to attempt to distinguish PBA from MCA. In
our series of nine cases, the predominant abnormality
was homozygous loss of 9p21 followed by polysomy pat-
tern and single chromosome gain (chromosomes 3, 7).
These findings however did not appear to be helpful indistinguishing PBA from SBA. Kipp et al [26]. studied
FISH findings using UroVysion probe sets in bladder
carcinoma variants. In their study, the most frequent
abnormality documented in bladder adenocarcinoma
was 9p21 homozygous loss followed by single gain only.
They did not find significant difference in the chromo-
somal abnormalities between the different tumor types.
This study, unlike ours, did not compare bladder adeno-
carcinoma with metastatic adenocarcinoma.
Conclusion
In summary, PBA is a rare and aggressive malignant
neoplasm of the urinary bladder that morphologically
mimics metastatic colorectal adenocarcinoma at the mor-
phological level and to some extent immunohisto-
chemically. A panel of antibodies comprised of β-catenin,
e-cadherin, CK7 and CDX-2 can be helpful in distin-
guishing PBA from MCA in the light of appropriate
clinical findings. Although FISH using the UroVysion
probe set demonstrated various chromosomal abnormal-
ities, it did not show significant differences between PBA
and MCA. The results of the study reemphasize the per-
sistence of the diagnostic challenge in distinguishing
PBA and MCA clinico-pathologically. However, small
cohort size was an important limitation of this study and
therefore larger studies are required to substantiate the
above conclusion. Moving further with question, It may
be of interest to investigate the molecular landscape of
the two tumors using high-throughput molecular ana-
lysis methods for possible diagnostic biomarkers.
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